Table 2 Clinical summary of the COVID-19 patients
Groups | Total (n = 19) | Survivors (n = 9) | Non survivors (n = 10) | p-value1 | |
|---|---|---|---|---|---|
Gender F|M | 11|8 | 6|3 | 5|5 | 0.650 | |
Age | ≤55 | 1(5.26%) | 1 (11.11%) | 0 (0%) | 0.474 |
56–65 | 5(26.31%) | 3 (33.33%) | 2 (20%) | 0.628 | |
66–75 | 5(26.31%) | 3 (33.33%) | 2 (20%) | 0.628 | |
76–85 | 6 (31.58%) | 0 (0%) | 6 (60%) | 0.018 | |
> 85 | 2(10.53%) | 0 (0%) | 2 (20%) | 0.210 | |
Ct qPCR | 23.2 | 23.2 | 24.05 | 0.2692 | |
Symptoms | |||||
Fever | 13 (68.42%) | 7 (77.78%) | 6 (60%) | 0.628 | |
Cough | 10 (52.63%) | 7 (77.78%) | 3 (30%) | 0.069 | |
Dyspnea | 9 (47.36%) | 2 (22.22%) | 7 (70%) | 0.069 | |
Odynophagia | 3 (15.79%) | 3 (33.33%) | 0 (0%) | 0.087 | |
Cefalea | 1 (5.26%) | 1 (11.11%) | 0 (0%) | 0.474 | |
Fever or Dyspnea | 17 (89.47%) | 8 (88.89%) | 9 (90%) | 1.000 | |
Cough or Dyspnea | 16 (84.21%) | 9 (100%) | 7 (70%) | 0.211 | |
Cough or Odynophagia | 12 (63.15%) | 5 (55.56%) | 7 (70%) | 0.649 | |
Comorbidities | |||||
Diabetes | 7 (36.84%) | 2 (22.22%) | 5 (50%) | 0.349 | |
Hypertension | 9(47.36%) | 5 (55.56%) | 5 (50%) | 1.000 | |
Respiratory diseases | 9(47.36%) | 2 (22.22%) | 5 (50%) | 0.349 | |
Cardiac diseases | 4 (21.05%) | 2 (22.22%) | 2 (20%) | 1.000 | |
Neurological diseases | 1(5.26%) | 1 (11.11%) | 0 (0%) | 0.473 | |
Diabetes or respiratory dis. | 12 (63.15%) | 3 (33.33%) | 9 (90%) | 0.019 | |
Diabetes or hypertension | 11 (57.89%) | 5 (55.56%) | 6 (60%) | 1.000 | |
Respiratory or hypertension | 15 (78.95%) | 6 (66.67%) | 9 (90%) | 0.303 | |
Hospitalization | 12 (63.15%) | 3 (33.33%) | 9 (90%) | 0.019 | |